Replies to post #664846 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

ILT,

People are smart. They can only be fooled once or twice. The declining numbers tell the real story.

Vaccination Trends Update:
The percent of the population reporting receipt of COVID-19, influenza, and RSV vaccines remains low for adults. Estimates for children will be updated next week.
The percent of the population reporting receipt of the updated 2023-24 COVID-19 vaccine is 21.4% (20.6-22.2) for adults 18+, including 41.5% (39.3-43.8) among adults age 65+.
The percent of the population reporting receipt of a flu vaccine is 46.8% (45.7-47.9) for adults 18+, including 74.1% (71.3-76.9) among adults age 65+.
The percent of adults age 60+ that report receiving an RSV vaccine is 20.1% (18.8-21.4).

Reported on Friday, January 12th, 2024..

https://www.cdc.gov/respiratory-viruses/data-research/dashboard/vaccination-trends-adults.html

I don't believe that Merck would pin its future on the mRNA stuff. It is highly risky. How could they find all the neopeptides that can trigger immune response? I feel like those specific type of neopeptides are as rare as diamond.

Here are the constructions of all the facilities at West Point. They were started in November. I don't think at the time that Merck made the decision on construction Merck had conclusive results on the trial of keytruda + mRNA.

https://www.uppergwynedd.org/board-commissioners/files/nov-2021-merck-63a-presentation
https://www.uppergwynedd.org/board-commissioners/files/oct-19-merck-presentation-b45
https://www.uppergwynedd.org/board-commissioners/files/feb-2021-merck-b50-presentation-0
https://www.uppergwynedd.org/board-commissioners/files/april-12-merck-b32-presentation